Alumis, Inc. (ALMS)
6.31
+0.25
(+4.13%)
USD |
NASDAQ |
Oct 15, 16:00
6.30
-0.01
(-0.16%)
After-Hours: 20:00
Alumis Research and Development Expense (Quarterly) : 84.46M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 84.46M |
| March 31, 2026 | 80.67M |
| December 31, 2025 | 76.52M |
| September 30, 2025 | 96.92M |
| June 30, 2025 | 107.88M |
| March 31, 2025 | 95.78M |
| December 31, 2024 | 86.38M |
| Date | Value |
|---|---|
| September 30, 2024 | 87.01M |
| June 30, 2024 | 47.80M |
| March 31, 2024 | 41.20M |
| December 31, 2023 | 33.88M |
| September 30, 2023 | 37.47M |
| June 30, 2023 | 32.73M |
| March 31, 2023 | 32.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Johnson & Johnson | 4.652B |
| Corcept Therapeutics, Inc. | 53.89M |
| Aclaris Therapeutics, Inc. | 18.07M |
| BioAge Labs, Inc. | 24.36M |
| ANI Pharmaceuticals, Inc. | 14.75M |